Traders should monitor the tender offer process and Hart-Scott-Rodino clearance timeline; TERN stock is likely to trade near the $53 offer price pending deal closure. The $2.35 per share earnings impact for Merck may pressure its near-term EPS, but long-term oncology pipeline diversification could support valuation. Watch for any competing bids or shareholder litigation risks.
Price Chart
Executive Summary
Merck will acquire Terns Pharmaceuticals for $53.00 per share in cash, representing a total equity value of $6.7 billion and a 31-42% premium to Terns' recent trading prices. The deal is driven by Terns' lead oncology candidate, TERN-701, a novel allosteric BCR::ABL1 inhibitor in development for chronic myeloid leukemia (CML), which Merck sees as a potential best-in-class therapy. The transaction is expected to close in Q2 2026, subject to shareholder and regulatory approvals.
Key Financial Metrics
Key Facts
- Merck is acquiring Terns for $53.00 per share in cash, a 31% premium to the 60-day and 42% to the 90-day volume-weighted average price.
- Total equity value of the deal is $6.7 billion, with net value of $5.7 billion after adjusting for acquired cash.
- TERN-701, Terns' lead asset, is an investigational oral allosteric BCR::ABL1 inhibitor in Phase 1/2 development for CML, with FDA Orphan Drug Designation granted in March 2024.
- Clinical data show promising major and deep molecular responses by week 24, including in heavily pretreated patients, with a favorable safety profile.
- The acquisition is structured as a tender offer and is expected to close in Q2 2026, subject to antitrust clearance and shareholder approval.
- Merck will record a $5.8 billion charge in Q2 2026 related to the acquisition, impacting both GAAP and non-GAAP earnings by $2.35 per share.
Financial Impact
$6.7 billion total equity value, $5.8 billion charge to Merck in Q2 2026
Risk Factors
- Deal may not close if a majority of Terns shareholders do not tender their shares.
- Regulatory delays or objections under antitrust review could push closing beyond Q2 2026.
- Clinical development risk: TERN-701 remains in early-stage trials and may not meet efficacy or safety endpoints in later studies.
- Merck's $5.8 billion charge could impact investor sentiment on near-term profitability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262042 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 15, 2026 20w ago | 15-12G | $52.97 awaiting T+1 | awaiting T+1 | — | — |
May 8, 2026 21w ago | EFFECT | $52.95 $52.95 | · 0.00% | ▼ −0.23% | — |
May 5, 2026 21w ago | 8-K | $52.95 $52.95 | · 0.00% | ▼ −1.38% | — |
May 5, 2026 21w ago | 25-NSE | $52.95 $52.95 | · 0.00% | ▲ +1.38% | — |
Apr 27, 2026 22w ago | 8-K | $52.95 $52.94 | ▼ −0.02% | ▲ +0.47% | — |
Apr 27, 2026 22w ago | Press Release | $52.95 $52.94 | ▼ −0.02% | ▲ +0.47% | — |
Mar 25, 2026 27w ago | Press Release | $52.86 $53.17 | ▲ +0.59% | ▲ +2.36% | — |
Feb 28, 2026 30w ago | Institutional Cluster | $42.03 $41.51 | ▼ −1.24% | ▼ −0.32% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access